Chronic graft rejection

doi:10.1016/0952-7915(94)90083-3

Current Opinion in Immunology

Volume 6, Issue 5, 1994, Pages 770-776

https://doi.org/10.1016/0952-7915(94)90083-3 Get rights and content

Abstract

Although chronic rejection remains the most crucial cause of organ graft loss over the long term, its etiology is not well defined. Early injury to graft endothelial cells caused by alloantigen-independent factors, such as ischemia or reperfusion, as well as alloantigen-dependent events, such as acute rejection, have been implicated. Macrophages and their products, peptide growth factors and adhesion molecules are all thought to play an important role in this process via the cytokine-adhesion molecule cascade. Although new immunosuppressive agents, including RS61443 or rapamycin, may be effective in preventing antigen-driven components of this condition, risk factors for initial non-immune injury must also be considered and, if possible, countered.

References (61)

N.L. Tilney et al.
Transplantation immunology: an Introduction
Transplant Immunol
(1994)
H.M. Isoniemi et al.
Long-Term Consequences of Different Immunosuppressive Regimens for Renal Allografts
Transplantation
(1993)
F.K. Merkel et al.
Is en Bloc Transplantaton of Small Pediatric Kidneys into Adult Recipients Justified?
M.E. Ferrero et al.
Improved Grafted Rat Heart Metabolic Function Using Defibrotide
J.P. Roberts et al.
Reversal of Chronic Rejection After Treatment Failure with FK506 and RS61443
Transplantation
(1993)
L.C. Paul et al.
Chronic Transplant Rejection: Magnitude of the Problem and Pathogenetic Mechanisms
Transplant Rev
(1993)
W.H. Hancock et al.
Cytokines, Adhesion Molecules, and the Pathogenesis of Chronic Rejection of Rat Renal Allografts
Transplantation
(1993)
P. Hayry et al.
Chronic Allograft Rejection
Immunol Rev
(1993)
H. Adams et al.
Chronic Rejection in Experimental Cardiac Transplantation: Studies in the Lewis-F344 Model
Immunol Rev
(1993)
B.C. Fellstrom et al.
Pathogenesis and Treatment Perspectives of Chronic Rejection (CVR)
Immunol Rev
(1993)

C.H. Ewel et al.

Chronic Graft Rejection: Accelerated Transplant Arteriosclerosis

Immunol Rev

(1993)

G.P. Basadonna et al.

Early Versus Late Acute Renal Allograft Rejection: Impact on Chronic Rejection

Transplantation

(1993)

P.S. Almond et al.

Risk Factors for Chronic Rejection in Renal Allograft Recipients

Transplantation

(1993)

R.J. Tesi et al.

Acute Rejection Episodes - Best Predictor of LongTerm Primary Cadaveric Renal Survival

K.A. Munger et al.

The Effects of Surgery and Acute Rejection on Glomerular Hemodynamics in Transplanted Rat Kidney

Transplantation

(1993)

A. Matas et al.

Half-Life and Risk Factors for Kidney Transplant Outcome-Importance of Death with Function

Transplantation

(1993)

J. Jones et al.

The Living Donor — Risks, Benefits, and Related Concerns

Transplant Rev

(1993)

S. Yilmaz et al.

The Impact of Acute Episodes of Rejection on the Generation of Chronic Rejection in Rat Renal Allografts

Transplantation

(1993)

F. Poli et al.

Genomic HLA-DR Compatibility in Long-Term Surviving Recipients of Cadaver Kidney Transplants

Transplantation

(1993)

G. Opelz et al.

Analysis of HLA-DR Matching in DNA-Typed Cadaver Kidney Transplants

Transplantation

(1993)

T. Kobayashi et al.

HLA-DRB1 Matching as a Recipient Selection Criterion in Cadaveric Renal Transplantation

Transplantation

(1993)

B. Meiser et al.

Graft Vessel Disease: The Impact of Immunosuppression and Possible Treatment Strategies

Immunol Rev

(1993)

A.K. Walli et al.

Role of Lipoproteins in Progressive Renal disease

Am J Hypertension

(1993)

S. Rubattu et al.

Influence of Hypercholesterolemia on Adrenal Steroid Metabolism and Electrolyte Balance in Spontaneously Hypertensive Rats

Endocrinology

(1993)

E. Dimeny et al.

Hyperlipoproteinemia in Renal Transplant Recipients: Is There a Linkage with Chronic Rejection?

J. Nilsson

Lipid Oxidation, Vascular Inflammation, and Coronary Atherosclerosis

R.P. Lowry et al.

Chronic Rejection of Organ Allografts May Arise from injuries Sustained in Recurring Foci of Acute Rejection that Resolve Spontaneously

Transplant Proc

(1993)

Z. Ding et al.

Influence of Warm Ischemia on Cyclosporin Nephrotoxicity in Renal Isografts in Rats

Transplant Proc

(1993)

J.R. Neuringer et al.

Glomerular Hypertension: Cause and Consequence of Renal Injury

J Hypertens

(1992)

B.M. Brenner et al.

Nephron Underdosing: A Programmed Cause of Chronic Renal Allograft Failure

Am J Kidney Dis

(1993)

Cited by (92)

Rat immunology
2019, The Laboratory Rat
The immune system plays a primary role in mechanisms of defense against disease and the maintenance of homeostasis for all species, including rats. With this chapter, we hope to highlight significant contributions from the rat to the field of immunology and provide a useful reference for non-immunologists who may use rat models in research. The reader is referred to more comprehensive immunology and laboratory animal textbooks for additional background on information throughout this chapter. This chapter provides a wide overview of important attributes and contributions for the rat in immunology and functions as a reference to enhance further exploration of rat biological models.
Prevention of intimal hyperplasia employing the cavitary two-layer method in allogeneic rat heart transplantation
2012, Journal of Surgical Research
Citation Excerpt :
Chronic rejection is a major threat to long-term graft survival in the period after acute rejection has been controlled [1, 2].
The development of graft arteriosclerosis is a significant contributor to chronic rejection in organ transplant recipients. The purpose of the present study was to establish whether or not the cavitary two-layer method can prevent graft arteriosclerosis after rat heart transplantation.
F-344 rats served as donors to Lewis recipients. Grafts in the control group (group C) were immediately allotransplanted without preservation. Grafts were also transplanted after cold preservation for 3 h in University of Wisconsin solution (group UW), or employing the cavitary two-layer (CTL) method (group TL). In another group (group W), grafts were subjected to 15-min warm ischemia and then transplanted. Grafts damaged by ischemia were also transplanted after preservation for 3 h using CTL (group WTL). We measured intimal thickening (IT) before transplantation and at 30 and 60 d post-transplant and also assessed the expression of heat shock proteins (HSPs).
At 60 d post-transplant, IT in group WTL was significantly lower than in group W (0.30 ± 0.03 versus 0.45 ± 0.04, respectively). In contrast, no significant changes were observed in the cold storage groups. Expression of HSPs 60 and 70 at 60 d in group WTL (25.40% ± 1.64% and 35.96% ± 2.65%, respectively) was reduced compared with group W (46.07% ± 5.84% and 55.11% ± 1.54%, respectively).
CTL reduces IT induced by warm ischemia in rat heart transplantation, and allows the maintenance of low HSP 60 and 70 expression.
Today in molecular mechanisms of immunosuppressive drugs actions: Roles of pharmacist
2008, Annales Pharmaceutiques Francaises
Les agents immunosuppresseurs sont capables de moduler la réponse immunitaire à médiation cellulaire et humorale, associée au rejet aigu de la greffe d’organe solide. L’arsenal thérapeutique récemment élargi, représente une avancée significative pour l’immunosuppression clinique et améliore les connaissances des voies de signalisation intervenant dans l’activation lymphocytaire. La classe thérapeutique la plus ancienne regroupe les corticoïdes dont le mécanisme d’action reste mal connu. Ils agissent sur plusieurs cytokines, telles que l’interleukine 2 (IL2) et l’interleukine 6 et représentent le traitement curatif du rejet aigu. Les autres traitements sont utilisés en prévention du rejet aigu et appartiennent à plusieurs classes différentes. La ciclosporine et le tacrolimus, après fixation à une immunophilline spécifique, inhibent la calcineurine, une sérine/thréonine phosphatase qui joue un rôle pivot dans la transcription des cytokines, notamment l’IL2, après activation des cellules T. Les anticorps monoclonaux antirécepteur à l’IL2 bloquent l’action de l’IL2 libérée par les lymphocytes T activés. Les agents inhibiteurs de la protéine mammalian target of rapamycin préviennent la transcription de différents ARNm intervenant dans la régulation du cycle cellulaire ; ces agents récemment commercialisés comprennent la rapamycine ou sirolimus et l’évérolimus. Enfin, des inhibiteurs de la synthèse des bases puriques et pyrimidiques, le mycophénolate mofétil ou sodique et l’azathioprine, respectivement, bloquent la prolifération cellulaire des lymphocytes T et B. La diversification des traitements immunosuppresseurs actuellement et prochainement disponibles permet le recours à des combinaisons à toxicité réduite, notamment la néphrotoxicité et à faible risque immunologique. Le pharmacien joue un rôle important, d’une part, en amont de la greffe dans la prévention des maladies initiales, ainsi que dans la politique des dons d’organes. D’autre part, après la transplantation, le pharmacien biologiste a un rôle dans le suivi pharmacologique des traitements et dans le suivi biologique de l’efficacité et des effets indésirables des thérapeutiques. Enfin, le pharmacien doit s’impliquer dans l’optimisation des traitements et l’éducation des patients ; le dossier pharmaceutique s’avère alors être un outil indispensable à cette mission.
Immunosuppressive drugs modulate cellular and humoral immune response in the acute allograft rejection. The panel of drugs, which has been recently extended, allowed a significant progress for immunosuppressive treatment. These drugs help us to improve our knowledge of lymphocyte activation pathways. Corticoids, the oldest immunosuppresive drugs, inhibit many cytokines such as interleukin 2 (IL2) and interleukin 6. They represent the treatment of acute rejection. The other immunosuppressive drugs are used for preventing acute rejection. After binding to a specific immunophillin, cyclosporin and tacrolimus inhibit calcineurine, a serine/threonine phosphatase which plays a major role in cytokines transcription notably IL2 after T-cell activation. Anti-IL2 receptor monoclonal antibodies block IL2 activity following T-cell activation. Protein mammalian target of rapamycin inhibitors avoid the transcription of different mRNA involved in the regulation of the cellular cycle. These new agents are rapamycin or sirolimus and everolimus. The inhibitors of pyrimidic and puric bases synthesis, mycophenolic acid and azathioprin, inhibit T- and B-cell proliferation. The wide variety of immunosuppressive drugs permits the use of combinations, which aims at decreasing the immunologic risk and their own toxicities, notably nephrotoxicity. Before transplant, the pharmacist plays an important role in the prevention of initial pathologies and in the politic of organ donation. After transplant, the pharmacist has a role in the pharmacological and biological monitoring of immunosuppressive drugs. But the pharmacist must be involved in the optimization of therapeutics and in the education of transplant patients.
Carvedilol Inhibits Platelet-Derived Growth Factor-Induced Extracellular Matrix Synthesis by Inhibiting Cellular Reactive Oxygen Species and Mitogen-Activated Protein Kinase Activation
2006, Journal of Heart and Lung Transplantation
Vascular smooth muscle cell (VSMC) proliferation, migration, and extracellular matrix (ECM) synthesis are major pathologic features of chronic allograft vasculopathy. Carvedilol, an anti-hypertensive agent, might be an effective agent for preventing the development and progression of chronic allograft vasculopathy, since it can inhibit VSMC proliferation and migration. The present study was designed to examine the effect of carvedilol on platelet-derived growth factor (PDGF)-induced ECM synthesis in rat VSMCs. Furthermore, we evaluated whether carvedilol inhibits PDGF-induced cellular reactive oxygen species (ROS) and the activation of mitogen-activated protein kinase (MAPK).
Primary cultured rat VSMCs were stimulated with PDGF-BB (10 ng/ml) in the presence or absence of carvedilol, and the effects of carvedilol were compared with those of ROS or MAPK inhibitors. Fibronectin secretion, proliferating cell nuclear antigen (PCNA) expression, and each MAPK activation were determined by Western blot analysis, total collagen synthesis by [³H]-proline incorporation, and cellular ROS by flow cytometry.
PDGF significantly increased PCNA expression, fibronectin secretion, total collagen synthesis, cellular ROS, and MAPK activation in rat VSMCs. Carvedilol at doses that inhibited PDGF-induced cell proliferation, inhibited ECM synthesis, cellular ROS, or subsequent MAPK activation. Structurally different anti-oxidants and extracellular signal-regulated protein kinase or p38 MAPK inhibitor effectively inhibited PDGF-induced fibronectin secretion and total collagen synthesis.
These results suggest that carvedilol inhibits PDGF-induced VSMC proliferation and matrix protein synthesis by inhibiting cellular ROS and the subsequent activation of MAPK. Thus the targeted inhibition of cellular ROS and MAPK might provide an effective therapeutic strategy to treat chronic allograft vasculopathy.
Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model
2006, Journal of Heart and Lung Transplantation
To explore a more effective and less toxic immunosuppressive strategy in organ transplantation, we recently developed the novel sphingosine-1-phosphate receptor agonist KRP-203. This study examined the efficacy of KRP-203 combined with mycophenolic acid (MPA), an active metabolite of mycophenolate mofetil, in rat heart allografts.
Heterotopic heart transplantation was performed in a rat combination of DA (MHC haplotype: RT1^a) to Lewis (RT1^l). The recipients were divided into 12 groups (n = 5–7): Syngeneic (Lewis to Lewis), Vehicle, KRP-203 (0.3 and 1 mg/kg), MPA (10 and 20 mg/kg), 10 mg/kg MPA with KRP-203 (0.03, 0.3, 1, and 3 mg/kg), and 20 mg/kg MPA with KRP-203 (0.3 and 1 mg/kg). MPA, KRP-203, and vehicle were given orally.
The mean days of survival were 5.8 (vehicle), 7 and 7.9 (0.3 and 1 mg/kg KRP-203, respectively), 12.7 and >54.4 (10 and 20 mg/kg MPA), >39.6 and >30.5 (10 mg/kg MPA with 1 and 3 mg/kg KRP-203), >100 and >87.8 (20 mg/kg MPA with 0.3 and 1 mg/kg KRP-203). Histologic and immunohistochemical analysis revealed that diffuse mononuclear cell infiltration (macrophages and T cells), hemorrhage, myocardial necrosis and fibrosis, and expression of endothelin-1, transforming growth factor-β1, monocyte chemoattractant protein-1, interleukin-8, and E-selectin were markedly diminished in the allografts treated with MPA combined with KRP-203. Pharmacokinetic experiments indicated no interaction between MPA and KRP-203, and both combination regimens were well tolerated.
Combination therapy of MPA with KRP-203 has a therapeutic potential as a novel immunosuppressant strategy in clinical transplantation.
Immunology
2006, The Laboratory Rat
Rats have been the backbone of many types of research, including immunology, immunogenetics, and transplantation. For example, Brown Norway (BN) rats are used as models of respiratory track allergy, and BN and Lewis (LEW) rats are used as models of several autoimmune diseases. Many homologs of human cluster of differentiation antigens have been cloned in the rat, further enhancing the importance of this species as an immunology research tool. Also, because rats are larger than mice, they lend themselves to a variety of well-established and novel microsurgical techniques that have proven to be valuable in addressing certain fundamental immunological issues. Moreover, the size of rats makes them the premier rodent choice for transplantation studies. A wide range of genetically well-defined inbred laboratory rat strains are available, and a variety of mutant, congenic, and recombinant inbred rat strains of immunological interest have been developed. Rats are also frequently used for hybridoma and monoclonal antibody production. Immunological experimentation in rats has been critical in biomedical research and will continue to be for many years to come.

View all citing articles on Scopus

View full text

Chronic graft rejection

Abstract

Transplant Immunol

Transplantation

Transplantation

Chronic Transplant Rejection: Magnitude of the Problem and Pathogenetic Mechanisms

Transplant Rev

Cytokines, Adhesion Molecules, and the Pathogenesis of Chronic Rejection of Rat Renal Allografts

Transplantation

Chronic Allograft Rejection

Immunol Rev

Chronic Rejection in Experimental Cardiac Transplantation: Studies in the Lewis-F344 Model

Immunol Rev

Pathogenesis and Treatment Perspectives of Chronic Rejection (CVR)

Immunol Rev

Chronic Graft Rejection: Accelerated Transplant Arteriosclerosis

Immunol Rev

Early Versus Late Acute Renal Allograft Rejection: Impact on Chronic Rejection

Transplantation

Risk Factors for Chronic Rejection in Renal Allograft Recipients

Transplantation

Acute Rejection Episodes - Best Predictor of LongTerm Primary Cadaveric Renal Survival

The Effects of Surgery and Acute Rejection on Glomerular Hemodynamics in Transplanted Rat Kidney

Transplantation

Half-Life and Risk Factors for Kidney Transplant Outcome-Importance of Death with Function

Transplantation

The Living Donor — Risks, Benefits, and Related Concerns

Transplant Rev

The Impact of Acute Episodes of Rejection on the Generation of Chronic Rejection in Rat Renal Allografts

Transplantation

Genomic HLA-DR Compatibility in Long-Term Surviving Recipients of Cadaver Kidney Transplants

Transplantation

Analysis of HLA-DR Matching in DNA-Typed Cadaver Kidney Transplants

Transplantation

HLA-DRB1 Matching as a Recipient Selection Criterion in Cadaveric Renal Transplantation

Transplantation

Graft Vessel Disease: The Impact of Immunosuppression and Possible Treatment Strategies

Immunol Rev

Role of Lipoproteins in Progressive Renal disease

Am J Hypertension

Influence of Hypercholesterolemia on Adrenal Steroid Metabolism and Electrolyte Balance in Spontaneously Hypertensive Rats

Endocrinology

Hyperlipoproteinemia in Renal Transplant Recipients: Is There a Linkage with Chronic Rejection?

Lipid Oxidation, Vascular Inflammation, and Coronary Atherosclerosis

Chronic Rejection of Organ Allografts May Arise from injuries Sustained in Recurring Foci of Acute Rejection that Resolve Spontaneously

Transplant Proc

Influence of Warm Ischemia on Cyclosporin Nephrotoxicity in Renal Isografts in Rats

Transplant Proc

Glomerular Hypertension: Cause and Consequence of Renal Injury

J Hypertens

Nephron Underdosing: A Programmed Cause of Chronic Renal Allograft Failure

Am J Kidney Dis